Clinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride.
Q1 2026
May 15, 2026
FY 2025
Dec 30, 2025
Q4 2025
Q3 2025
Sep 29, 2025
Q2 2025
Jun 30, 2025
